Bausch Health Companies Inc. (NYSE:BHC) Director John Paulson Purchases 1,005,376 Shares

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) Director John Paulson bought 1,005,376 shares of the business's stock in a transaction dated Thursday, June 12th. The shares were bought at an average cost of $5.47 per share, with a total value of $5,499,406.72. Following the purchase, the director now directly owns 29,227,643 shares of the company's stock, valued at approximately $159,875,207.21. This represents a 3.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

John Paulson also recently made the following trade(s):

• On Wednesday, June 11th, John Paulson acquired 1,029,098 shares of Bausch Health Companies stock. The shares were acquired at an average cost of $5.24 per share, with a total value of $5,392,473.52.
• On Tuesday, June 10th, John Paulson purchased 754,134 shares of Bausch Health Companies stock. The stock was purchased at an average cost of $5.05 per share, with a total value of $3,808,376.70.

Bausch Health Companies Stock Performance

Bausch Health Companies stock traded up $0.51 during midday trading on Friday, hitting $6.02. 11,490,808 shares of the company's stock were exchanged, compared to its average volume of 2,611,854. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $9.85. The stock has a market cap of $2.23 billion, a price-to-earnings ratio of -50.12, a price-to-earnings-growth ratio of 0.37 and a beta of 0.28. The firm's 50 day simple moving average is $4.85 and its 200 day simple moving average is $6.41.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on BHC shares. Wall Street Zen lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a report on Saturday, May 10th. Royal Bank of Canada raised their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $7.42.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Nomura Holdings Inc. lifted its stake in shares of Bausch Health Companies by 106.2% in the 1st quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company's stock worth $151,366,000 after acquiring an additional 12,050,000 shares during the period. Vanguard Group Inc. raised its position in Bausch Health Companies by 0.5% during the first quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock worth $76,152,000 after acquiring an additional 61,621 shares during the last quarter. Franklin Resources Inc. raised its position in Bausch Health Companies by 1.1% during the fourth quarter. Franklin Resources Inc. now owns 5,316,822 shares of the company's stock worth $42,855,000 after acquiring an additional 56,446 shares during the last quarter. Maple Rock Capital Partners Inc. grew its holdings in shares of Bausch Health Companies by 156.7% during the fourth quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock worth $42,718,000 after buying an additional 3,235,100 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Bausch Health Companies by 46.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock worth $38,501,000 after buying an additional 1,510,445 shares in the last quarter. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.